Home > Healthcare > Medical Devices > Therapeutic Devices > us dialysis market
Get a free sample of U.S. Dialysis Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of U.S. Dialysis Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on type, the market is categorized into hemodialysis and peritoneal dialysis. The hemodialysis segment dominated the market with a revenue of around USD 25.4 billion in 2023.
Based on product and services, the U.S. dialysis market is categorized into services, consumables, and equipment. The service segment dominated the market in 2023 with a market share of around 78.3%.
Based on end-use, the U.S. dialysis market is categorized into in-center dialysis and home dialysis. The in-center dialysis segment dominated the market in 2023 and is anticipated to reach USD 38.3 billion by the end of forecast period.
The South Atlantic dialysis market accounted for USD 6.5 billion market revenue in 2023 and is anticipated to grow at CAGR of 5.1% between 2024 – 2032 period.
Northeast dialysis market is projected to grow remarkably in the coming years.
South Atlantic U.S. dialysis industry size is anticipated to grow at 5.1% CAGR between 2024 and 2032 led by rapidly aging population in Florida, Georgia, and North and South Carolina
Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, DaVita Inc., Fresenius Medical Care AG & Co., Innovative Renal Care., Medtronic plc, Nikkiso Co., Ltd., Nipro Corporation, Toray Industries Inc., and U.S. Renal Care, Inc.
The hemodialysis type segment in the market recorded USD 25.4 billion in 2023 as it is the standard treatment for the majority of patients with ESRD, particularly those who may not be candidates for home-based therapies.
U.S. dialysis industry was valued at USD 28.8 billion in 2023 and is expected to exhibit 5.5% CAGR from 2024 to 2032 attributed to the rising number of end-stage renal diseases (ESRD) patients and increasing incidence of diabetes